Literature DB >> 7954467

The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo.

V Grégoire1, N T Van, L C Stephens, W A Brock, L Milas, W Plunkett, W N Hittelman.   

Abstract

We have previously reported that fludarabine, an adenine nucleoside analogue, significantly enhances radiation-induced tumor regrowth delay and local cure in several mouse tumors. Although fludarabine potentiated tumor regrowth delay at various times from -36 h to +6 h in a SA-NH mouse sarcoma model, the greatest enhancement was observed when fludarabine was administered 24 h before irradiation. The purpose of this study was to understand the basis for in vivo enhancement of radiation efficacy by fludarabine. To examine the effect of fludarabine on DNA synthesis and cell cycle progression, tumor-bearing mice were given fludarabine by an i.p. route and then bromodeoxyuridine at various times up to 36 h, followed 0.5 h later by tumor harvest. Two-parameter flow cytometry analysis of the tumor cells using an anti-bromodeoxyuridine antibody demonstrated that an 800-mg/kg fludarabine dose stops DNA synthesis within 3 h with recovery starting at 12 h. By 24 h after fludarabine treatment, a synchronized wave of cycling tumor cells appeared in G2-M phase. The degree of DNA synthesis shutdown and the timing of the reinitiation of DNA synthesis and cell cycle progression were all fludarabine dose dependent. Interestingly, DNA synthesis reinitiated only at the G1-S boundary; cells in the S phase at the time of fludarabine administration appeared to disappear from the tumor population. To confirm these observations more directly, we pretreated tumor-bearing mice i.p. with chlorodeoxyuridine to mark the cells in the S phase, gave them fludarabine 0.5 h later, and then gave them iododeoxyuridine 0.5 h before tumor harvest. Flow cytometry analysis using antibodies specific for chlorodeoxyuridine- and iododeoxyuridined-labeled cells confirmed that cells in the S phase at the time of fludarabine administration never reinitiated DNA synthesis and disappeared from the tumor population. Immunohistological analysis of tumor sections obtained after fludarabine administration demonstrated that prelabeled S-phase cells took on an apoptotic appearance and gradually disappeared from the tumors. An in situ DNA end labeling assay demonstrated DNA fragmentation in these morphologically apoptotic cells. These results suggest that the mechanism of fludarabine enhancement of radiation response involves induced S-phase cell loss through an apoptotic pathway and subsequent synchronization of the remaining cells to a more radiosensitive cell cycle phase at the time of irradiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954467

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

2.  Combined effects of cisplatin and photon or proton irradiation in cultured cells: radiosensitization, patterns of cell death and cell cycle distribution.

Authors:  Hiromitsu Iwata; Tsuyoshi Shuto; Shunsuke Kamei; Kohei Omachi; Masataka Moriuchi; Chihiro Omachi; Toshiyuki Toshito; Shingo Hashimoto; Koichiro Nakajima; Chikao Sugie; Hiroyuki Ogino; Hirofumi Kai; Yuta Shibamoto
Journal:  J Radiat Res       Date:  2020-11-16       Impact factor: 2.724

3.  2-[18F]fludarabine, a novel positron emission tomography (PET) tracer for imaging lymphoma: a micro-PET study in murine models.

Authors:  Martine Dhilly; Stéphane Guillouet; Delphine Patin; Fabien Fillesoye; Ahmed Abbas; Fabienne Gourand; Olivier Tirel; Françoise Galateau; Eric T MacKenzie; Charles Dumontet; Michel Leporrier; Louisa Barré
Journal:  Mol Imaging Biol       Date:  2014-02       Impact factor: 3.488

4.  (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  Mol Cancer Ther       Date:  2012-01-11       Impact factor: 6.261

5.  Susceptibility of ATM-deficient pancreatic cancer cells to radiation.

Authors:  Michael Ayars; James Eshleman; Michael Goggins
Journal:  Cell Cycle       Date:  2017-04-28       Impact factor: 4.534

6.  Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.

Authors:  Qing Chang; Mark S Chapman; Jeffrey N Miner; David W Hedley
Journal:  BMC Cancer       Date:  2010-09-28       Impact factor: 4.430

7.  Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-29       Impact factor: 7.038

8.  Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation.

Authors:  Jennifer Tseng; Deborah E Citrin; Meryl Waldman; Donald E White; Steven A Rosenberg; James C Yang
Journal:  Cancer       Date:  2014-01-28       Impact factor: 6.860

9.  Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation.

Authors:  Diane E Milenic; Kwamena E Baidoo; Joanna H Shih; Karen J Wong; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2013-06-11       Impact factor: 3.099

10.  Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study.

Authors:  Mirko Nitsche; Hans Christiansen; Katinka Lederer; Frank Griesinger; Heinz Schmidberger; Olivier Pradier
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-10       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.